Literature DB >> 33495204

Inappropriate direct oral anticoagulant prescriptions in patients with non-valvular atrial fibrillation: cross-sectional analysis of the French CACAO cohort study in primary care.

Emilie Ferrat1, Julie Fabre2, Philippe Galletout2, Emmanuelle Boutin3, Julien Le Breton1, Vincent Renard1, Paul Frappé4, Sylvie Bastuji-Garin5.   

Abstract

BACKGROUND: Direct oral anticoagulants (DOACs) account for an increasing proportion of prescriptions in patients with non-valvular atrial fibrillation (NVAF) in primary care. Inappropriate dosing of DOACs is a common problem, with under-dosing being a particular issue. However, conflicting results have been reported about the factors independently associated with inappropriate dosing. AIM: To describe inappropriate prescriptions of DOACs among patients in the CACAO French nationwide general practice cohort, and to identify the factors independently associated with inappropriate DOAC doses. DESIGN AND
SETTING: Cross-sectional baseline analysis of the CACAO French national multicentre prospective cohort of adult patients in primary care receiving an oral anticoagulant who were recruited between April and October 2014.
METHOD: A total of 1111 patients from the CACAO cohort who received a DOAC for NVAF were included in this study. Inappropriate prescriptions of DOACs were described (inappropriate dosage, contraindications, non-indications, interactions, and non-compliance with the precautions for use). Multivariate logistic models were used to investigate factors associated with inappropriate DOAC dosing (under-dosing and over-dosing).
RESULTS: Overall, 438 patients (39.4%) received at least one inappropriate DOAC prescription. The most common inappropriate prescription was inappropriate dosage (n = 374, 33.7%), particularly under-dosing (n = 348, 31.3%). Multivariate analysis revealed that factors independently associated with under-dosing were older age, prescription of apixaban or dabigatran, and a CHA2DS2-VASc score ≥2 vs. a score = 1. Factors with over-dosing were kidney failure, a HAS-BLED score ≥3, and older age.
CONCLUSION: The appropriateness of DOAC prescribing for NVAF can be improved, especially in older patients, and in patients with kidney failure, a higher risk of ischaemic stroke, and/or a higher risk of bleeding. GPs have a key role in increasing the proportion of appropriate DOAC prescriptions via informational, educational, and/or management strategies.
© The Authors.

Entities:  

Keywords:  atrial fibrillation; cohort studies; direct oral anticoagulants; prescription; primary care; public health

Mesh:

Substances:

Year:  2021        PMID: 33495204      PMCID: PMC7846350          DOI: 10.3399/bjgp20X714005

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  14 in total

1.  Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.

Authors:  Martín Ruiz Ortiz; Javier Muñiz; Paula Raña Míguez; Inmaculada Roldán; Francisco Marín; María Asunción Esteve-Pastor; Angel Cequier; Manuel Martínez-Sellés; Vicente Bertomeu; Manuel Anguita
Journal:  Europace       Date:  2018-10-01       Impact factor: 5.214

2.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.

Authors:  Benjamin A Steinberg; Peter Shrader; Laine Thomas; Jack Ansell; Gregg C Fonarow; Bernard J Gersh; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; James Reiffel; Daniel E Singer; Eric D Peterson; Jonathan P Piccini
Journal:  J Am Coll Cardiol       Date:  2016-12-20       Impact factor: 24.094

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld
Journal:  Eur J Cardiothorac Surg       Date:  2016-09-23       Impact factor: 4.191

4.  Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation.

Authors:  Katy Lavoie; Marie-Hélène Turgeon; Caroline Brais; Josiane Larochelle; Lucie Blais; Paul Farand; Geneviève Letemplier; Sylvie Perreault; Marie-France Beauchesne
Journal:  J Atr Fibrillation       Date:  2016-12-31

5.  The Dose of Direct Oral Anticoagulants and Stroke Severity in Patients with Acute Ischemic Stroke and Nonvalvular Atrial Fibrillation.

Authors:  Yuji Kato; Takeshi Hayashi; Norio Tanahashi; Masaki Takao
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-02-03       Impact factor: 2.136

6.  Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants.

Authors:  Molly Howard; Andrew Lipshutz; Breanne Roess; Emily Hawes; Zachariah Deyo; Jena Ivey Burkhart; Stephan Moll; Betsy Bryant Shilliday
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

7.  Effect of Renal Function on Dosing of Non-Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With Nonvalvular Atrial Fibrillation.

Authors:  Sulena Shrestha; Onur Baser; Winghan Jacqueline Kwong
Journal:  Ann Pharmacother       Date:  2017-08-31       Impact factor: 3.154

8.  Areas of improvement in anticoagulant safety. Data from the CACAO study, a cohort in general practice.

Authors:  Paul Frappé; Joël Cogneau; Yoann Gaboreau; Nathan Abenhaïm; Marc Bayen; Matthieu Calafiore; Claude Guichard; Jean-Pierre Jacquet; François Lacoin; Laurent Bertoletti
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

9.  Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study.

Authors:  Rikke Sørensen; Gunnar Gislason; Christian Torp-Pedersen; Jonas Bjerring Olesen; Emil L Fosbøl; Morten W Hvidtfeldt; Deniz Karasoy; Morten Lamberts; Mette Charlot; Lars Køber; Peter Weeke; Gregory Y H Lip; Morten Lock Hansen
Journal:  BMJ Open       Date:  2013-05-03       Impact factor: 2.692

10.  Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010-2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network.

Authors:  Finlay A McAlister; Scott Garrison; Leanne Kosowan; Justin A Ezekowitz; Alexander Singer
Journal:  J Am Heart Assoc       Date:  2018-01-26       Impact factor: 5.501

View more
  1 in total

Review 1.  Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction.

Authors:  Balbir Singh; Paresh Pai; Harish Kumar; Sheeba George; Sandeep Mahapatra; Vineet Garg; G N Gupta; Kiran Makineni; Gaurav Ganeshwala; Pravin Narkhede; Syed M H Naqvi; Kumar Gaurav; Mohammed Y K Hukkeri
Journal:  Cardiol Ther       Date:  2022-02-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.